Permente

Quick links to important sections

Permente

Method of action: Psychoanaleptics

Treatment option: Dementia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Permente

Quick Facts

Property Description
Active ingredient Rivastigmine (typically as Rivastigmine tartrate)
Form Capsule, Oral solution, Transdermal patch
Pharmacological class Cholinesterase Inhibitor
General purpose Symptomatic support of memory and thinking ability
Origin Synthetic (Carbamate derivative)

What Type of Medicine is Permente (Rivastigmine)?

Permente is a prescription-only medicine whose active component is the synthetic substance Rivastigmine. The drug belongs to the high-level therapeutic category of cholinesterase inhibitors, a specific group of pharmacological agents that act centrally within the nervous system. Rivastigmine acts as an inhibitor of both acetylcholinesterase and butyrylcholinesterase enzymes, defining its dual-action property. This dual mechanism is recognized for its role in supporting fundamental cognitive processes.

Rivastigmine is chemically classified as a carbamate derivative, a distinct chemical structure that defines its pharmacological profile. As a centrally acting cholinesterase inhibitor, the medicine's identity is defined by its core purpose: the general enhancement of cholinergic function.

Composition, Forms, and General Purpose

Permente is produced as a single-active ingredient product, containing only Rivastigmine as the therapeutic agent, combined with specialized pharmaceutical excipients or a polymer matrix. A distinctive feature is its availability in multiple pharmaceutical preparations—specifically the oral capsule, the oral solution, and the transdermal patch. Delivery occurs either orally for the liquid and capsule forms or transdermally through the skin via the patch.

The general purpose of the medicine is related directly to its inhibitory mechanism: by temporarily preventing the rapid breakdown of acetylcholine, Permente effectively increases the concentration of this essential chemical messenger. This therapeutic approach is intended to improve or stabilize symptoms by sustaining the level of acetylcholine in the brain. This action is designed to support the existing capacity for memory and thinking ability.

Regulatory References

  1. NIH MedlinePlus Drug Information on Rivastigmine
  2. MedlinePlus Rivastigmine Information

What side effects are possible with Permente?

Possible Side Effects and Safety Information

The safety profile of Permente (Rivastigmine) is classified by regulatory authorities based on the affected organ system and the frequency of occurrence. Gastrointestinal and Nervous System disorders are the most frequently documented adverse reactions, with risk patterns related to the timing of treatment.

Frequency-Classified Adverse Reactions

Official labels define the likelihood of adverse reactions using standardized terminology:

Classification Examples of Documented Effects
Very Common (> 1 in 10) Nausea, vomiting, diarrhea, dizziness, headache
Common (≤ 1 in 10) Loss of appetite, somnolence (drowsiness), tremor, fatigue, agitation
Uncommon (≤ 1 in 100) Syncope (fainting), bradycardia (slow heart rate), peptic ulcers
Rare (≤ 1 in 1,000) Seizures (convulsions), upper gastrointestinal bleeding

Serious Safety Considerations

Serious adverse reactions, though rare, are highlighted in regulatory documents and include severe gastrointestinal hemorrhage, pancreatitis, significant bradycardia, and the development of hepatitis (liver inflammation). Gastrointestinal effects may be severe enough to cause dehydration.

Population and Contextual Safety Notes

The incidence of gastrointestinal adverse reactions is documented as being more common during the initial phase of treatment and following dose escalation. Specific constraints apply to certain patient groups: the medicine is not recommended for use in individuals with severe hepatic impairment, and caution is required in patients with low body weight (under 50 kg), as they may be at a higher risk of adverse effects. Caution is also advised in patients with a history of active peptic ulcer disease.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Permente


Overdose Scope

Category Official Regulatory Statement
Documented overdose presentations Presentation is characterized by severe manifestations of cholinergic crisis. Symptoms reported include severe nausea, severe vomiting, diarrhea, increased salivation, convulsions (seizures), confusion, and increased sweating.
Physiological systems affected (as stated in label) Cardiovascular (bradycardia, cardiac arrhythmia, hypertension), Neurological (seizures, confusion), Respiratory (shallow breathing), and Systemic (shock, increasing muscle weakness).
Dose-related or exposure-related factors (if applicable) Overdose has been reported due to medication errors, specifically failing to remove the old patch or wearing multiple patches simultaneously. The incidence and severity of adverse reactions are dose-related.
Population-specific overdose notes (if applicable) Patients with low body weight (less than 50 kg) require careful monitoring for toxicities. Dehydration from prolonged vomiting/diarrhea can lead to serious outcomes.
Emergency-response statements (as written in official documents) All transdermal patches must be immediately removed. Patients must seek immediate emergency medical attention or contact a Poison Control Centre. Treatment is symptomatic and supportive.
When immediate medical help is required (label-derived phrasing only) Seek immediate emergency medical attention at once. Medical attention is required even if there are no symptoms (following a known overdose).

Overdose Classifications (High-Level)

Category Official Regulatory Statement
Severity classification (as defined in official documents) Serious adverse reactions, including cases requiring hospitalization and, rarely, death, have been reported due to overdose.
Regulatory basis (EMA / FDA / etc.) Information derived from FDA Prescribing Information and EMA Summary of Product Characteristics.
Overdose-context constraints (as defined in official documents) The profile is defined by cholinergic crisis arising from excessive cholinesterase inhibition.

Resulting Overdose Structure

Official overdose statements:

  • Cholinergic Overdose Syndrome: Overdose symptoms include severe gastrointestinal effects, confusion, and neurological manifestations like seizures, which define the cholinergic crisis.
  • Life-Threatening Risks: Documented severe outcomes include shock, severe cardiac arrhythmia, and respiratory compromise, necessitating immediate emergency care.
  • Mandated Immediate Action: All patches must be immediately removed, and the patient or caregiver must seek immediate emergency medical attention as directed by regulatory guidance.

Connection to the overall overdose profile (3 sentences): The official regulatory documents strictly define the overdose profile by detailing the clinical presentation of a cholinergic crisis and explicitly establishing the conditions under which immediate emergency help is required. The guidance emphasizes that the removal of the transdermal patch is a critical first step in limiting exposure, while hospitalization is often required for continuous cardiac monitoring and supportive management. The lack of a known specific antidote further underscores the severity of the documented toxic effects.

Therapeutic Uses of Permente

Managing Dementia in Alzheimer's and Parkinson's Disease

Permente (Rivastigmine) may be part of symptomatic management for neurodegenerative dementias, specifically addressing cognitive symptoms experienced by patients with Alzheimer's disease and dementia associated with Parkinson's disease. The medication is relevant in conditions characterized by periods of heightened symptoms across the spectrum of mild to moderate severity, and is also considered relevant for severe Alzheimer's disease dementia. The treatment aims to support the patient during the progression of the condition by helping with existing memory and thinking ability, and may be relevant when functional stability becomes affected.

The core indications for which this medicine is commonly used are Alzheimer's disease dementia and Parkinson's disease dementia. By addressing the symptomatic cluster involving core cognitive impairment, the medicine may assist with managing difficulty with memory loss, impaired judgment, and confusion. “It supports general well-being during symptomatic phases and helps patients cope more steadily with symptom fluctuations.” This assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Cognitive Decline
Therapeutic Focus: Supports existing memory and thinking ability during the course of the condition.
Contributes to easing functional strain: Supports the management of symptoms that interfere with daily functioning.
Relevant for symptoms related to: confusion and orientation deficits.

Regulatory References

  1. NIH MedlinePlus overview on Rivastigmine

Eligibility and Restrictions for Use

Who Can and Cannot Use Permente?

The population eligible to use Permente (rivastigmine) is strictly defined by official regulatory documents, primarily focusing on adult patients with mild to moderately severe dementia.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults with mild to moderately severe Alzheimer's dementia or Parkinson's disease-associated dementia.
Populations for whom use is not recommended Patients with severe dementia (oral formulation) and children and adolescents (under 18 years), as use is not relevant in the pediatric population.
Populations for whom use is contraindicated Patients with known hypersensitivity to rivastigmine, other carbamate derivatives, or any component of the formulation.
Pregnancy and lactation eligibility status Should not be used during pregnancy unless clearly necessary. Women should not breast-feed while undergoing treatment.

Eligibility Classifications

Category Official Regulatory Classification
Eligibility severity classification Contraindicated (Absolute prohibition due to allergy), Not Recommended (Pediatric use/Severe dementia), Use with Caution (Organ impairment/Comorbidities).
Eligibility-context constraints Must be used with care in patients with: heart conduction defects, active ulcers, history of asthma, and those predisposed to urinary obstruction or seizures.

Connection to the overall eligibility profile:

Regulatory documents define eligibility by establishing absolute prohibitions for patients with known allergies and exclusionary rules for those under 18 years old. For eligible adults, the profile enforces conditional use where specific pre-existing conditions, such as organ impairment or cardiac conduction issues, mandate an officially designated level of caution or close monitoring to adhere to labeled restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products


The official interaction profile for Permente (Rivastigmine) is structured around two main domains: pharmacodynamic effects and pharmacokinetic modifications.

Pharmacodynamic Interactions

Co-administration with other cholinomimetic substances (including other cholinesterase inhibitors) is officially not recommended due to the potential for additive effects resulting in increased cholinergic activity. Caution is necessary when the drug is combined with bradycardia-inducing agents, such as beta-blockers (e.g., atenolol) or digitalis glycosides, as this may lead to additive effects causing a slow heart rate (bradycardia) and possible syncope. The medicine may also interfere with the activity of anticholinergic medicinal products, such as oxybutynin, potentially reducing their therapeutic effect. During general anesthesia, Rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants. Regulatory text suggests that temporarily stopping treatment or adjusting the dose may be considered prior to the use of a succinylcholine-type muscle relaxant.

Pharmacokinetic and Clearance Notes

Rivastigmine’s metabolism shows minimal involvement of CYP450 isoenzymes, indicating a low potential for clinically significant metabolic drug-drug interactions via this pathway. For the oral forms, co-administration with food modifies the pharmacokinetics, causing a reduction in peak plasma concentration (Cmax) and a 30% increase in overall exposure (AUC). Furthermore, patients with mild to moderate hepatic impairment are noted to have increased systemic exposure to the drug.

Mechanism of Action

The mechanism of Permente is rooted in the dual inhibition of two key enzymes in the central nervous system: Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE). The active molecule forms a stable chemical bond with the enzymes through a process called carbamylation, temporarily deactivating them and halting the hydrolysis of the neurotransmitter Acetylcholine (ACh). .

By blocking the enzymatic destruction of Acetylcholine, the drug enables a preservation of this critical messenger in the synaptic clefts between neurons. This increased availability of ACh leads to a prolonged and enhanced stimulation of the cholinergic receptors, which is the resulting physiological modulation of synaptic function in brain regions associated with cholinergic signaling.

Permente's binding is pseudo-irreversible, meaning the functional blockade of the enzymes persists for many hours after the drug itself has been cleared from the body. This unique kinetic profile extends the duration of enhanced cholinergic activity, decoupling the pathway effect from the drug's rapid systemic clearance, and modulating neural communication across two related enzymatic control points.

Dosage and Administration Information

Permente (permethrin 5% cream) is a topical medication used for the treatment of scabies. It is intended for external use only. Consult a healthcare provider before use, especially for children under two months of age.

Application Instructions

  1. Preparation: Ensure the skin is clean, cool, and dry. Do not apply immediately after a hot bath or shower. Fingernails and toenails should be trimmed to facilitate proper application beneath them.
  2. Coverage: Thoroughly massage a thin layer of the cream into all skin surfaces from the neck down to the soles of the feet. For infants and the elderly, the cream should also be applied to the scalp, hairline, neck, and temples.
  3. Key Areas: Pay special attention to skin folds, creases, the spaces between fingers and toes, under the nails, the groin, and the buttocks. Avoid contact with the eyes and mucous membranes. If accidental contact occurs, flush immediately with water.
  4. Duration and Removal: Leave the cream on the skin for 8 to 14 hours. After the recommended time, wash the medication off completely by taking a shower or bath.

Follow-up Treatment

A single application is often sufficient, but a second application is typically necessary to ensure elimination of all mites and newly hatched eggs. The second treatment should be performed 7 days after the first, following the same instructions. Post-treatment itching may persist for up to four weeks due to an allergic response to the dead mites and does not necessarily indicate treatment failure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Permente

Evidence for Use in Alzheimer's Disease Dementia

Research examined Permente for its evaluation in Alzheimer's disease dementia, a condition characterized by fluctuating or episodic manifestations of cognitive and functional decline. The primary evidence base consists of numerous large-scale Randomized Controlled Trials (RCTs) that involved comparing the medicine to a placebo (inactive substance). Systematic Reviews and Meta-analyses compiling data from multiple trials have explored how symptoms changed over time in the observed populations. Researchers used standardized rating scales to measure outcomes reflecting daily functioning alongside measures for cognitive function like memory and thinking ability.

Research for Mild to Moderate Stages

The core of the clinical evidence was observed in adults with a confirmed diagnosis of mild to moderate Alzheimer's disease dementia. The studies involved monitoring patients over short-term periods, typically around six months. Findings describe patterns observed in the studies related to these core cognitive and functional measures. When research examined behavioral symptoms and the outcomes related to caregiver burden, findings were mixed across different studies compiled in the systematic reviews.

Evidence for Use in Parkinson's Disease Dementia

Permente was also studied for its evaluation in patients diagnosed with dementia associated with Parkinson's disease (PDD). This research primarily involved placebo-controlled RCTs applied in research contexts involving fluctuating or unstable symptoms related to the underlying condition. Regulatory reviews noted that research reports tracked the balance between observed changes in cognitive outcomes and the occurrence of motor-related events that may be associated with the underlying Parkinson's disease.

Long-Term Studies and Observation Periods

Research provides insight into short-term changes, with the definitive, controlled trials for both indications having follow-up durations that were limited (typically around six months). Long-term outcomes in controlled settings are not fully characterized. Data from open-label studies was observed in some patients over periods extending beyond one year, primarily collecting observational data rather than focusing on sustained cognitive function measures.

Evidence Gaps and Areas of Uncertainty

A major area of uncertainty is that the research does not include evaluations of whether the medicine affects the underlying neurodegenerative process that causes these diseases. Furthermore, data show patterns related to core cognitive measures, but the magnitude of these changes may be described as modest when viewed across all compiled research.

Frequently Asked Questions (FAQ)

Common questions about Permente (FAQ)


Q: What are the most common side effects listed for Permente in official documents?

According to official safety documents, side effects are classified by how often they occur. Effects listed as 'Very Common' (occurring in more than 1 in 10 people) include digestive issues like nausea, vomiting, and diarrhea, as well as nervous system effects such as dizziness and headache.


Q: Does Permente interact with common over-the-counter pain relievers?

Regulatory documents note that the medicine is used with caution when combined with nonsteroidal anti-inflammatory drugs (NSAIDs). This is because the drug's mechanism may increase gastric acid secretion, and this combination may carry a higher risk for gastric issues.


Q: Is it true that Permente can cause changes in appetite or weight?

Official safety information lists a Loss of appetite as a common adverse reaction for this medication. Weight loss has also been noted in regulatory reports, particularly in specific patient populations such as those with a low body weight or those receiving higher doses.


Q: Are there any specific foods or drinks that should be avoided while using Permente?

For the oral forms (capsule and solution), regulatory documents indicate that administering the medicine with food changes how it is absorbed by the body. This information describes how the medicine's absorption may be affected, particularly concerning the peak concentration of the drug in the bloodstream.


Q: What should be done if a user forgets to take a dose of Permente?

Official product information suggests that if a dose is missed, users should typically proceed with the next scheduled dose rather than attempting to double the amount. Consult the official Patient Information Leaflet for specific details.


Q: Are there any known differences between the brand name and generic versions of Permente?

The U.S. FDA approves a generic version only after regulatory testing confirms it is bioequivalent to the brand-name product. The goal of establishing bioequivalence is to ensure that the generic is absorbed similarly to the brand name and is thus acceptable for substitution.


Q: How quickly should a person expect to feel the effects of Permente?

Pharmacokinetic data shows that the drug reaches its highest concentration in the blood approximately one hour after the oral form is taken. However, this measurement of drug concentration in the bloodstream does not directly indicate when a person may notice the therapeutic benefits.


Q: Is Permente meant to be taken for a short period of time or long-term?

While the main controlled clinical trials typically monitored patients for a period of around six months, regulatory documents note that open-label studies have observed some patients over periods extending beyond one year. This suggests that the duration of treatment may extend over a long period.


Q: How is Permente different from other medicines used for the same condition?

Regulatory text defines Permente as a cholinesterase inhibitor that is unique due to its ability to cause dual inhibition. This means it works by blocking the activity of both the acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes.


Q: Why do some people refer to Permente as a 'slow-acting' medication?

The drug's mechanism involves a bond that is described as pseudo-irreversible. This causes the functional blockade of the target enzymes to persist for many hours, meaning the intended effect continues long after the drug itself has been cleared from the body.


Q: What is the official risk classification for using Permente during pregnancy?

The U.S. FDA classifies this drug under Pregnancy Category B. This classification is defined by regulatory standards where animal studies have not demonstrated a risk to the fetus, but adequate, controlled studies in pregnant women are not available.


Q: Is it safe to drive or operate machinery while taking Permente?

Official regulatory labels include a specific warning stating that the medicine may affect a patient's coordination, reaction time, or judgment. For this reason, official guidance recommends caution when the medicine is used and before engaging in complex tasks such as operating machinery or driving.


Q: Can a person stop taking Permente suddenly, or does it require gradual discontinuation?

Regulatory reviews note that the cessation of treatment is a clinical consideration, and there is uncertainty about the effects of sudden withdrawal from the drug. Decisions regarding the cessation of treatment should be reviewed by a prescribing healthcare provider.


Q: How long does Permente stay in the body after the last dose?

The time it takes for half of the drug to be eliminated from the body, known as the elimination half-life, is approximately 1.5 hours. The majority of the dose is removed from the body via the kidneys, with roughly 97% recovered in the urine over five days.


Q: Can older adults use Permente, or is there an age restriction/warning?

The drug is approved for use in adults. Population studies noted in regulatory text indicate that the drug's clearance—the rate at which it is removed from the body—was approximately 30% lower in elderly subjects compared to younger subjects.


Q: Is it normal to feel a difference in energy level when starting Permente?

Official adverse reaction lists include both fatigue and somnolence (drowsiness) as common side effects. Experiencing a change in energy or feeling tired is noted as a possibility when initiating treatment.


Q: How does Permente affect other chronic medications, such as those for blood pressure?

Regulatory documents specifically advise caution when the drug is combined with bradycardia-inducing agents, such as certain beta-blockers. This is due to potential additive effects that can lead to a slow heart rate (bradycardia).


Q: Can Permente be used safely while breastfeeding?

Official regulatory information advises that a decision must be made to either discontinue breastfeeding or discontinue the drug. This decision involves weighing the importance of the drug to the mother's health against the potential effects on the nursing infant.


Q: Do men and women experience different side effects when taking Permente?

Population pharmacokinetic analysis included in regulatory documents indicated that gender did not affect the clearance of the oral drug. The official adverse reaction profile is generally compiled across the entire patient population without specific differences based on sex.


Q: Is Permente available in different forms (e.g., liquid, tablet, injection)?

The medicine is available in three official dosage forms listed in regulatory documents: an oral capsule, an oral solution, and a transdermal patch that is applied to the skin. Injection is not listed as one of the official dosage forms.


Q: Can Permente be safely used by teenagers under the age of 18?

Official regulatory labels confirm the drug is not recommended for use in children and adolescents (under 18 years). This is because the medical conditions the drug is approved to treat are not relevant in the pediatric population.

How should Permente be stored and disposed of?

How to Store and Dispose of Permente (Rivastigmine)

The official storage requirements for Permente (Rivastigmine) vary slightly by form but prioritize temperature control and container integrity. All forms must be stored out of the sight and reach of children.

Storage Conditions

Item Requirement (Official Regulatory Statement)
Temperature Store capsules and patches at Controlled Room Temperature, 20 C to 25 C. Do not freeze the capsules or transdermal patches.
Protection Keep the medicine in its original container; capsules must be protected from moisture. Patches must remain sealed until immediate use.
Stability Limit The Oral Solution must be used within 30 days after first opening; discard any remaining product after this period.

Disposal Instructions

Unused or expired Permente must not be thrown into household trash or flushed down the toilet. Disposal requires taking the medicine to a pharmacy or a local drug take-back collection program, consistent with official regulatory instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Permente found in:

A-Z Index: